Table 1. Diseases involving the respiratory tract and hypereosinophilia [1].

	Adult-onset eCRSwNP	EGPA	N-ERD	Adult-onset asthma	ABPA
Prevalence (asthma/CRS patients)	3 – 10%	0.6%	5 – 10%	21 – 48%	2.5%
M : W	2 : 1	1 : 2	1 : 2	2 : 3	1 : 1
Appearance at the age of...	30 – 50	56	35 – 36	30 – 46	25 – 55
under 12	Rare	Rare	Rare	n.a.	Rare
over 60	Rare	Possible	Rare	Possible	Possible
Clinical peculiarity	Nasal polyps, loss of smell	Systemic vasculitis, granulomatosis	Salicylate intolerance	Rapid decrease in LuFu	Mucus plugs (bronchial tubes)
Biomarkers
Blood-Eo	↑	↑↑↑	↑	↑↑	↑↑↑
Serum IgE (IU/mL)	Variable	100 – 300	Variable	Variable	1,000 – 10,000
FeNO	↑	↑	↑	↑	↑
Serum periostin	↑	↑→	↑	↑	↑↑
U LTE4	↑	↑↑	↑↑↑
EETs/EETosis	++Lumen/tissue	Possible		++Lumen/tissue	++Lumen
Charcot-Leyden crystals	++Lumen/tissue	Possible		++Lumen/tissue	++Lumen
Other	CST-1, eotaxin-3, IgG4	ANCA, eotaxin-3, lösIL-2R	Mast cell/ tile marker	Reversibility in LuFu for diagnosis
Response to biologics
anti-IgE	+	+	+	+	+
anti-IL-5(R)	++	++	+	++	++
anti-IL-4R	++		++	++
anti-TSLP	(+)			++

eCRSwNP = eosinophilic chronic rhinosinusitis with nasal polyps; EGPA = eosinophilic polyangiitis with granulomatosis; N-ERD = non-steroidal-exacerbated respiratory disease; ABPA = allergic bronchopulmonary aspergillosis; LuFu = lung function test; FeNO = fractional expiratory NO; leukotriene E4 = LTE4; EETs/EETosis = extracellular eosinophil traps; ANCA = antineutrophil cytoplasmic antibody.